Latest research on Pantoprazole

Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Latest findings

CYP2C19 inhibitors included Omeprazole and esOmeprazole, and CYP2C19 non-inhibitors included dexlansoprazole, lansoprazole, Pantoprazole, and Rabeprazole [18,19]. [source, 2016]
Pantoprazole and dexlansoprazole were the only PPIs with a significant increased use post-safety communication (3.9% vs. 6.1% and 0.0% vs. 0.5%, respectively) ( [source, 2016]
Patients transferring from CYP2C19 inhibitors mainly took the non-inhibitor PPIs Pantoprazole and dexlansoprazole. [source, 2016]
The proportion of patients using a combination with Pantoprazole increased almost three-fold in the post- vs. the pre-safety-communication period (OR = 2.96; p < 0.001) ( [source, 2016]
In the current study, the main decreases were observed for esomeprazole, followed by lansoprazole; which were partially replaced by Pantoprazole and dexlansoprazole. [source, 2016]
When the FDA released a reminder in October 2010, suggesting Pantoprazole as a viable alternative [16], physicians may have been more inclined to switch patients or to start prescribing Clopidogrel combination therapy with a treatment that was available as a generic (the generic version of Pantoprazole had been available since 2008, see S1 Table). [source, 2016]
Pantoprazole and dexlansoprazole are the only two PPIs that had an increase in their prescription trends during the post-safety communication period. [source, 2016]
Indeed, in October 2010, the FDA released a reminder warning against only Omeprazole in combination with Clopidogrel and suggesting Pantoprazole as an alternative [16]. [source, 2016]
In October 2011 the Pantoprazole and dexlansoprazole drug labels were changed to indicate no important clinical impact on Clopidogrel metabolism [21,22]. [source, 2016]
In addition, studies published in 2010 [23] and 2011 [24] for Pantoprazole and in 2012 for dexlansoprazole [25] showed reduced metabolic drug-drug interaction with Clopidogrel, compared to Omeprazole. [source, 2016]